[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360517-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-360517-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","rivaroxaban-versus-low-molecular-weight-heparin-for-cancer-associated-venous-thromboembolism-a-systematic-review-and-meta-analysis","Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism - A Systematic Review and Meta-Analysis","","Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, is a serious complication in cancer patients. This systematic review and meta-analysis compares rivaroxaban with low-molecular-weight heparins (LMWHs) for cancer-associated VTE. Using PRISMA-guided searches in PubMed, Cochrane Library, Google Scholar, and ClinicalTrials.gov through May 2025, it pools risk ratios with random-effects models. Results synthesize 25 studies to assess recurrence and mortality, supported by RoB, NOS, sensitivity, and GRADE.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/rivaroxaban-versus-low-molecular-weight-heparin-for-cancer-associated-venous-thromboembolism-a-systematic-review-and-meta-analysis/360517/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/rivaroxaban-versus-low-molecular-weight-heparin-for-cancer-associated-venous-thromboembolism-a-systematic-review-and-meta-analysis/360517.png","ImageObject",300,407,{"name":42,"@type":43},"Grenda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the document’s main comparison and clinical focus?","Question",{"text":63,"@type":64},"It compares rivaroxaban versus low-molecular-weight heparins (LMWHs) for treating cancer-associated venous thromboembolism (VTE). The focus includes efficacy and safety outcomes, especially VTE recurrence and all-cause mortality.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the evidence gathered and analyzed?",{"text":68,"@type":64},"Following PRISMA guidelines, studies were searched in PubMed, Cochrane Library, Google Scholar, and ClinicalTrials.gov from inception to May 2025. Risk ratios with 95% confidence intervals were pooled using a random-effects model.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings regarding recurrence and mortality?",{"text":72,"@type":64},"Rivaroxaban significantly reduced VTE recurrence compared with LMWH (RR 0.88, 95% CI 0.78–0.99, P=0.03) and also reduced all-cause mortality (RR 0.83, 95% CI 0.69–0.99, P=0.04). Other outcomes showed no statistically significant differences.",{"name":74,"@type":61,"acceptedAnswer":75},"What uncertainty remains and what does the conclusion recommend?",{"text":76,"@type":64},"GRADE certainty ranged from high to very low across the evidence. The conclusion notes that further large-scale randomized controlled trials are needed to confirm rivaroxaban’s safety profile.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},360517,1790181742,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis  \nClinical and Applied Thrombosis/Hemostasis Volume 32: 1–18 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/10760296261459711](DOI: 10.1177/10760296261459711)  \n[journals.sagepub.com/home/cat](journals.sagepub.com/home/cat)  \nZahabia Adnan1, Syed Ibad Hussain1, Amna Amir Jalal1, Ayesha Shaukat2, Eisha Abid1, Muhammad Burhan2, Arsalan Ahmed3, Eshal Saghir2, Shaikh Muhammad Daniyal2, Shanza Shakir3, Abedin Samadi4, and Ahmed Asad Raza1   \nAbstract  \nIntroduction: Venous thromboembolism (VTE), which includes DVT and PE is a serious complication in cancer patients. This meta-analysis evaluates the efficacy and safety of rivaroxaban compared to LMWHs in treating cancer-associated VTE. Methods: Following PRISMA guidelines, we searched PubMed, Cochrane Library, Google Scholar, and [ClinicalTrials.gov](ClinicalTrials.gov) from inception to May 2025 for studies comparing rivaroxaban with low-molecular-weight heparins (LMWHs) in adults with cancerassociated VTE. Primary outcomes were VTE recurrence and all-cause mortality. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using a random-effects model. Risk of bias was assessed using RoB and NOS, with sensitivity and GRADE analyses performed. Results: Twenty-five studies (n = 19,153, Rivaroxaban: 5186; LMWH: 13967) were included. Rivaroxaban significantly reduced the risk of VTE recurrence compared to LMWH (RR = 0.88; 95% CI: 0.78-0.99; P = 0.03) . Rivaroxaban also significantly reduced all-cause mortality compared to LMWH (RR = 0.83; 95% CI: 0.69-0.99; P = 0.04) . However, no statistically significant differences were noted in other outcomes. GRADE assessment showed evidence certainty ranged from high to very low. Conclusion: Rivaroxaban demonstrates lower all-cause mortality compared with LMWH, indicating a potential advantage in managing cancer-associated VTE. However, further large-scale RCTs are warranted to confirm its safety profile.  \nKeywords  \nrivaroxaban, low-molecular-weight heparin, venous thromboembolism, cancer-associated thrombosis, meta-analysis Received: 28 February 2026; Revised: 5 May 2026; Accepted: 29 May 2026  \n1. Introduction  \nVenous thromboembolism refers to clot formation indifferent veins of body which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and often life-threatening complication in cancer patients.1 This condition is a major  \n1Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan 2Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan  \n3Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan 4Department of Medicine, Kabul University of Medical Sciences Abu Ali Sina, Kabul, AfghanistanKabul  \nCorresponding author:  \nAbedin Samadi, Department of Medicine, Kabul University of Medical Sciences Abu Ali Sina, Jamal Mena Road, Ataturk Avenue, Kabul 1006, Afghanistan.  \nEmail: [abedinsamadi4@gmail.com](abedinsamadi4@gmail.com)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)).  \ncause of morbidity and the second leading cause of death in people with cancer. Moreover, the hypercoagulable state associated with cancer has been shown to contribute to tumor progression, independent of VTE events themselves. Hence also referred to","cbCaiqFgH8kaTn1t","https://ap.wps.com/l/cbCaiqFgH8kaTn1t","pdf",5367771,18,"English","# Introduction\n## Background: VTE and cancer-associated VTE\n## Conventional treatment and limitations\n# Methods\n## Search strategy and study selection\n## Outcomes and statistical approach\n# Results\n## Included studies and participant counts\n## Efficacy outcomes and mortality\n# Discussion and Conclusion\n## Interpretation of evidence and need for further RCTs","[{\"question\":\"What is the document’s main comparison and clinical focus?\",\"answer\":\"It compares rivaroxaban versus low-molecular-weight heparins (LMWHs) for treating cancer-associated venous thromboembolism (VTE). The focus includes efficacy and safety outcomes, especially VTE recurrence and all-cause mortality.\"},{\"question\":\"How was the evidence gathered and analyzed?\",\"answer\":\"Following PRISMA guidelines, studies were searched in PubMed, Cochrane Library, Google Scholar, and ClinicalTrials.gov from inception to May 2025. Risk ratios with 95% confidence intervals were pooled using a random-effects model.\"},{\"question\":\"What were the key findings regarding recurrence and mortality?\",\"answer\":\"Rivaroxaban significantly reduced VTE recurrence compared with LMWH (RR 0.88, 95% CI 0.78–0.99, P=0.03) and also reduced all-cause mortality (RR 0.83, 95% CI 0.69–0.99, P=0.04). Other outcomes showed no statistically significant differences.\"},{\"question\":\"What uncertainty remains and what does the conclusion recommend?\",\"answer\":\"GRADE certainty ranged from high to very low across the evidence. The conclusion notes that further large-scale randomized controlled trials are needed to confirm rivaroxaban’s safety profile.\"}]","Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism - A Systematic Review and Meta-Analysis | PDF",1790140343,45,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90afd31b3a856c330f5c7c4f65258ef3.webp",983,1310,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02bc8cec287aca9e741deebc2fe3962e.webp",982,1309,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35d6f1554b420a0088df492d47598c2d.webp",981,1308,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e555e147dabb0d1c46c4c62244049cc3.webp",980,1306]